“AstraZeneca” confirms that its vaccine caused “rare” blood clots


The British company, “AstraZeneca”, confirmed that its vaccine against the Coronavirus could cause “rare” cases of blood clots.

This came during a study supervised and funded by the company, which was published on the website of the British medical newspaper “The Lancet” on Tuesday.


The study indicated that the company’s vaccine could result in “rare blood clots with a decrease in the number of platelets after receiving the first dose.”

And the company added in its study that “there are no additional risks of blood clots after receiving the second dose of it.”

“Since the launch of the company’s vaccine, very rare cases of thrombosis with vaccine-induced thrombocytopenia (TTS) have been reported,” the report read.

The study found that the estimated incidence of thrombosis with thrombocytopenia syndrome (TTS) after receiving the first dose of the vaccine was 8.1 per million vaccinated people.

The study relied on analyzing all cases of clotting that occurred within 14 days of receiving the first or second dose of the “AstraZeneca” vaccine until April 30th.


And last June, Marco Cavalieri, a senior official at the European Medicines Agency, advised stopping vaccination with the AstraZeneca vaccine against Corona for all age groups if alternative vaccines were available.

Cavalieri indicated that he prefers “to use the (American) Johnson & Johnson vaccine for those over the age of sixty because it has fewer problems than AstraZeneca.”

And last March, reports of an unusual blood clot (particularly in the head) prompted some European countries to suspend the use of “AstraZeneca” for a certain period in all age groups.

However, the European Medicines Agency confirmed on the 18th of the same month that the effectiveness of the vaccine is more than its harm, and recommended its reuse after an evaluation of its side effects.


After the European Agency’s decision, several countries resumed the use of the British vaccine, while countries including Italy, Spain, and Australia restricted its use to those over 60 years old.

It is noteworthy that “AstraZeneca” and “Johnson & Johnson” are both viral vector vaccines that are based on another virus that is modified to provide the body with genetic information that allows the fight against Corona.